Pharmacovigilance Automation Market to Reach USD 5.25 Billion by 2035, Driven by AI and NLP Adoption
核心洞察
The global pharmacovigilance automation market was valued at USD 2.80 billion in 2025 and is projected to reach USD 5.25 billion by 2035, growing at a CAGR of 6.50%.
Artificial intelligence dominated the technology segment with a 41.30% market share in 2025, while natural language processing is the fastest-growing segment at a CAGR of 13.73%.
North America held the largest regional share at 38.60% in 2025, with the U.S. market alone valued at USD 0.94 billion and over 2 million adverse event reports filed annually into the FDA's FAERS database.
The global pharmacovigilance automation market is undergoing a significant transformation, with its valuation reaching USD 2.80 billion in 2025 and projected to climb to USD 5.25 billion by 2035, according to a new report from SNS Insider. The market is expected to grow at a compound annual growth rate (CAGR) of 6.50% during the 2026–2035 forecast period, fueled by the rising adoption of AI-powered pharmacovigilance platforms, increasing adverse event reporting requirements, and growing demand for automated drug safety monitoring solutions.
"More than 90% of the big pharma companies in regulated markets are now using digital systems for adverse event reporting and connected digital safety databases," the report states, underscoring how automation has become standard rather than aspirational across the pharmaceutical industry.
Technology Landscape: AI and NLP Lead the Charge
Artificial intelligence held the dominant position in the pharmacovigilance automation market with a 41.30% share in 2025, driven by its increasing use in automating adverse event reporting and signal management processes. AI enables rapid mining of safety data from unstructured text such as patient notes and research papers, while cloud computing allows global teams to access data in a timely manner for reporting purposes, reducing manual work and enabling faster drug safety decisions.
Natural language processing (NLP) emerged as the fastest-growing technology segment, with a projected CAGR of 13.73%. This growth is attributed to increasing demand for extracting safety insights from unstructured healthcare data sources, including physicians' notes, scientific literature, and social media adverse event monitoring across multiple languages.
Deployment Trends: Cloud and SaaS Models Accelerate
The cloud-based deployment segment captured a 49.80% market share in 2025 and is forecast to grow at a CAGR of 16.0% over the forecast period. Adoption of cloud-based pharmacovigilance systems is being boosted by reduced costs and ease of integration with AI technologies. The Software-as-a-Service (SaaS) segment is expected to record the highest CAGR of 13.02%, as subscription-based deployment models ensure faster implementation and automated software updates for pharmaceutical and biotechnology companies seeking flexible, cost-effective, and remotely accessible pharmacovigilance platforms.
Component and End-User Dynamics
Software dominated the pharmacovigilance automation market with a 72.40% share in 2025, reflecting the high use of drug safety automation solutions by pharmaceutical companies to process adverse events, generate signals, and perform regulatory activities. The services segment is the fastest-growing component category with a CAGR of 8.77%, driven by increasing demand for implementation, integration, validation, and outsourced pharmacovigilance services.
Pharmaceutical companies led the end-user segment with a 58.60% market share in 2025, owing to large drug portfolios and significant investment in AI-based safety systems. Biotechnology companies represent the fastest-growing end-user segment at a CAGR of 11.57%, as rapid growth in biologics and precision medicine pipelines with complex safety requirements drives adoption of pharmacovigilance automation among firms with limited internal pharmacovigilance infrastructure.
Regional Analysis: North America Leads, Europe and Asia-Pacific Surge
North America held a dominant position in the global pharmacovigilance automation market in 2025 with a share of approximately 38.60%. The U.S. market alone was valued at USD 0.94 billion in 2025 and is projected to reach USD 1.52 billion by 2035, growing at a CAGR of 4.95%. The United States remains one of the largest domestic markets, with over 2 million adverse event reports filed annually into the FDA's FAERS database. Nearly 96% of non-federal acute care hospitals have certified EHR systems capable of automatically integrating real-world data and generating safety signals into pharmacovigilance workflows.
Europe's pharmacovigilance automation market is expected to grow from USD 0.34 billion in 2025 to USD 1.92 billion by 2035, at a robust CAGR of 18.9%. The EudraVigilance database handles more than 2 million individual case safety reports annually, with electronic reporting compliance exceeding 95% among EU marketing authorization holders. Germany accounts for approximately 24.80% of European revenues, with France, the United Kingdom, and Italy providing consistent secondary demand.
The Asia-Pacific region is the fastest-growing regional market with a CAGR of approximately 8.92%. Over 70% of the region's member states have implemented effective pharmacovigilance systems aligned with WHO safety monitoring standards, and the region now contributes more than 25% of the world's Individual Case Safety Reports.
Industry Developments
Recent innovations highlight the market's momentum. In 2026, Oracle Corporation (搜索) introduced next-generation AI pharmacovigilance automation tools designed to increase the speed and efficiency of safety case processing and global regulatory compliance. In 2025, IQVIA Holdings Inc. enhanced its safety surveillance analytics platform, leveraging AI and real-world data to improve pharmacovigilance signal detection globally across pharmaceutical and biotechnology clients.
Pharmaceutical companies, biotechnology firms, contract research organizations, and drug safety service providers are increasingly investing in pharmacovigilance automation software to improve compliance, reduce operational costs, and accelerate regulatory submissions across global markets.